- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
We're at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease.
With U.S. troops deployed around the world, it is our mission to both protect U.S. military personnel and serve the international community by reducing risk of HIV-1 infection.
MHRP is at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease. While its primary focus is developing a globally effective HIV-1 vaccine, the program provides prevention, care and treatment through the President’s Emergency Plan for AIDS Relief (PEPFAR).
MHRP is centered at the Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Materiel Command.
MHRP was authorized by Congress in 1986, and since has become a leader in international efforts to combat HIV. With five sites in Africa and Asia, the program’s growth has been achieved through the combination of strong vaccine science, the careful development of research sites, and partnerships with key research institutions in the U.S. and host countries.
The integration of prevention, care and treatment has helped MHRP build strong and trusting relationships with the communities in which research is conducted, while providing an ethical framework to conduct HIV clinical research.
The program’s network includes international laboratory and clinical research capabilities. MHRP has developed research sites in Tanzania, Kenya, Nigeria, Uganda and Thailand. MHRP’s main laboratories are located in Rockville, Maryland.
MHRP's Dr. Jintanat Anaworanich heads the scientific journal and authors an editorial with Dr. Fauci on HIV cure research.
On World AIDS Day (Dec. 1), two leading HIV researchers are calling on the global community to renew the sense of urgency around developing a safe and effective vaccine against HIV/AIDS.
This prestigious award, given by Her Royal Highness Princess Soamsawali on World AIDS Day, recognizes her contributions to the advancement of HIV care and research in Thailand.
New findings published this week in the Journal of Infectious Diseases found HIV-1 viral load and subtype to be the primary predictors of disease progression in rural Uganda.
The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa.